Jazz Pharmaceuticals plc (JAZZ)

Market Cap	6.38B
Revenue (ttm)	4.06B
Net Income (ttm)	482.20M
Shares Out	61.63M
EPS (ttm)	7.51
PE Ratio	13.79
Forward PE	13.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,659,628
Open	99.43
Previous Close	97.78
Day's Range	99.13 - 105.28
52-Week Range	95.49 - 148.06
Beta	0.38
Analysts	Strong Buy
Price Target	181.85 (+75.57%)
Earnings Date	May 6, 2025

About JAZZ

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enry...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2007
• Employees: 2,800
• Stock Exchange: NASDAQ
• Ticker Symbol: JAZZ
• Website: https://www.jazzpharma.com

Financial Performance

In 2024, Jazz Pharmaceuticals's revenue was $4.07 billion, an increase of 6.12% compared to the previous year's $3.83 billion. Earnings were $560.12 million, an increase of 35.02%.

Analyst Forecast

According to 13 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price forecast is $181.85, which is an increase of 75.57% from the latest price.

Price Target

$181.85

(75.57% upside)

Analyst Consensus: Strong Buy